Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H39NO5 |
| Molecular Weight | 505.6451 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COCC(=O)[C@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)C5=CC=C(C=C5)N(C)C)OC(C)=O
InChI
InChIKey=JVBGZFRPTRKSBB-MJBQOYBXSA-N
InChI=1S/C31H39NO5/c1-19(33)37-31(28(35)18-36-5)15-14-27-25-12-8-21-16-23(34)11-13-24(21)29(25)26(17-30(27,31)2)20-6-9-22(10-7-20)32(3)4/h6-7,9-10,16,25-27H,8,11-15,17-18H2,1-5H3/t25-,26+,27-,30-,31-/m0/s1
| Molecular Formula | C31H39NO5 |
| Molecular Weight | 505.6451 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22028249 | https://clinicaltrials.gov/ct2/show/NCT01728454 | https://clinicaltrials.gov/ct2/show/NCT00874302 | https://www.globenewswire.com/news-release/2017/07/17/1047288/0/en/Repros-Announces-Proellex-Development-Program-Will-Remain-on-Partial-Clinical-Hold-by-the-FDA.html | https://clinicaltrials.gov/ct2/show/NCT01800422https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C104057
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22028249 | https://clinicaltrials.gov/ct2/show/NCT01728454 | https://clinicaltrials.gov/ct2/show/NCT00874302 | https://www.globenewswire.com/news-release/2017/07/17/1047288/0/en/Repros-Announces-Proellex-Development-Program-Will-Remain-on-Partial-Clinical-Hold-by-the-FDA.html | https://clinicaltrials.gov/ct2/show/NCT01800422https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C104057
Telapristone is an orally available 21-substituted-19-nor-progestin and selective progesterone receptor modulator (SPRM), with potential anti-progesterone and antineoplastic activities. Its acetate form, the telapristone Acetate is a clinically used and a studied drug.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells. | 2018-10-01 |
|
| A peek into the drug development scenario of endometriosis - A systematic review. | 2017-06 |
|
| Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance. | 2011-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01728454
Endometriosis: capsules (6 and 12 mg), once a day for 18 weeks
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:59:39 GMT 2025
by
admin
on
Mon Mar 31 19:59:39 GMT 2025
|
| Record UNII |
1K9EYK92PQ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1891
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
UU-07
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
C104055
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
SUB193704
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105694
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
C461063
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
100000178102
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
DB05253
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
198414-31-2
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
DTXSID60173587
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
1K9EYK92PQ
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY | |||
|
9806190
Created by
admin on Mon Mar 31 19:59:39 GMT 2025 , Edited by admin on Mon Mar 31 19:59:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLITE ACTIVE -> PRODRUG |
|
||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
PLASMA
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|